News Releases and Coverage

Pilot Study Uses CRP, Calprotectin to Diagnose Pulmonary Exacerbations (SPH)

(Photo credit: Cystic Fibrosis News Today)
(Photo credit: Cystic Fibrosis News Today)

Blood C-reactive protein (CRP) and calprotectin levels can reliably identify pulmonary exacerbations in cystic fibrosis (CF) patients, making them promising diagnostic biomarkers, a pilot study has found.

Although further investigations are necessary to determine their clinical applicability, the researchers note that “a step-wise algorithm that incorporates both absolute and fold-change cut-offs can increase the diagnostic performance of these biomarkers.”

The pilot study included 19 patients enrolled in a longitudinal CF blood biomarker study at St. Paul’s Hospital Adult CF Clinic in Vancouver, from July 2012 to August 2018. The group of patients analyzed was 63.2% male (12 of 19) with a mean age of 40.8 yeas and a total of 102 clinic visits, of which 56 were stable and 46 were during pulmonary exacerbations.

Click here for the full story on Cystic Fibrosis News Today.